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Background
First pass perfusion CMR is a well-validated technique
for the detection of inducible myocardial ischaemia.
However, limited data are available on the feasibility of
first pass perfusion CMR and quantitative deconvolution
analysis in the context of reduced LV function.
The aim of this study was to assess effects of reduced
LV function and LV dilatation on the characteristics of
signal in the left ventricle (arterial input function, AIF)
and in the myocardium (MSI), and to test the feasibility
of quantitative perfusion analysis with Fermi deconvolu-
tion in this cohort of patients.
Methods
We retrospectively identified fifteen consecutive patients
who had undergone perfusion CMR in the presence of
impaired LV function (left ventricular ejection fraction
(LVEF) <50%) at our centre. Five healthy volunteers
were enrolled in the study as control subjects. Perfusion
data were obtained using a pre-bolus technique and
0.075 mmol/kg Gadobutrol (Gadovist, Schering,
Germany) injected at 4ml/minute followed by a 20 ml
saline flush. Images were acquired on a Philips Achieva
3T (TX) system, equipped with a 32-channel cardiac
phased array receiver coil (Philips, Best, Netherlands).
First-pass perfusion images were acquired using a satura-
tion recovery gradient echo method (TR/TE 3.0 ms/
1.0 ms, flip-angle 15°; effective k-t SENSE acceleration 3.8,
spatial resolution 1.2x1.2x10 mm, saturation-recovery
delay 120 ms).
The following parameters were evaluated from stress
perfusion series in order to assess the quality of the data
and assess the effect of abnormal cardiac structure and
function: time to peak, peak value and maximum slope
of the AIF and of the MSI. Quantitative analysis was
performed by Fermi deconvolution.
Results
Detailed results are reported in Table. The left ventricular
(LV) systolic function was lower, with higher end-diastolic
(LV EDV) and end-systolic volumes (LV ESV) in the
patient compared with the normal group.
Both the AIF and the MSI were reduced in peak ampli-
tude, maximum upslope and time to peak in patients com-
pared with controls. However, the ratio between the peak
of AIF and MSI and the time to peak of the AIF and MSI
was constant between patients and controls, suggesting
the feasibility of deconvolution quantitative analysis on
both groups.
Fermi deconvolution showed a trend towards an overall
lower perfusion rate in normal segments in the patients
group (2.2±1.2 ml/g/min) compared with controls (2.7
±0.8; p=0.2) however non-significant. Reduced perfusion
rate was found in visually abnormal segments in patients
(1.6±0.8; p=0.03).
Conclusions
Our results show that reduced cardiac function modulates
the characteristics of both the AIF and MSI. However, the
relationship between AIF and MSI remains unaffected.
Fermi deconvolution analysis appears applicable to both
groups, supporting the feasibility of first pass perfusion
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Table 1 Showing values across patient and control group
Patient group Control group p value
LVEF (%) 40.1 (SD 9.4) 67.0 (SD 3.7) <0.0001
LV EDV (ml) 108.3 (SD 34.0) 75.6 (SD 7.8) 0.0030
LV ESV (ml) 67.1 (SD 31.1) 25.2 (SD 4.1) 0.0001
Peak AIF 389.4 (SD 328.2) 1239.7 (SD 637.8) 0.0379
Peak MSI 113.5 (SD 83.4) 358.4 (SD 199.4) 0.0497
Peak AIF / peak MSI 3.6 (SD 1.4) 3.7 (SD 0.7) 0.9054
Time to peak LVAIF (seconds) 9.1 (SD 3.2) 6.1 (SD 0.8) 0.0052
Time to peak MSI (seconds) 12.1 (SD 4.5) 7.6 (SD 1.0) 0.0025
Time to peak MSI / time to peak AIF (seconds) 3.1 (SD 3.7) 1.5 (SD 0.5) 0.1250
Figure 1 a) LVEF vs peak LV AIF, b) LV EDV vs LV AIF, c) LV EF vs peak LVAIF/peak MSI, d) LV EDV vs peak LVAIF/peak MSI.
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